Skip to main content
S. 3013 116th Congress Senate

Encouraging Innovative Benefit Design to Lower Costs for Seniors Act

Official title: A bill to amend title XVIII of the Social Security Act to allow for the offering of additional prescription drug plans under Medicare part D.

Introduced: December 10, 2019 See on congress.gov
Health Government information and archivesHealth care costs and insuranceHealth care coverage and accessInsurance industry and regulation
More subjectsShow fewer subjects
MedicarePrescription drugs
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 10, 2019
Read twice and referred to the Committee on Finance.
Dec 10, 2019
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action December 10, 2019

Read twice and referred to the Committee on Finance.

 Plain-English summary Congressional Research Service

Encouraging Innovative Benefit Design to Lower Costs for Seniors Act

This bill allows prescription drug plan (PDP) sponsors under the Medicare prescription drug benefit to offer additional plans in a region.

Specifically, the Centers for Medicare & Medicaid Services (CMS) must update guidance to allow PDP sponsors to offer up to four plans in a region; the CMS may also set a greater limit, as appropriate.

PDP sponsors may offer up to two additional plans beyond this limit if the PDP sponsor ensures that, under at least one of the plans, pharmacy benefit managers do not receive any remuneration unless at least 10% of price reductions received from drug manufacturers are reflected at the point-of-sale or otherwise used to reduce beneficiary cost-sharing.

 Related & companion bills 2
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act. 116th Congress. Open America. https://openamerica.io/bill/116-S-3013/
MLA
"S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-3013/.
Bluebook (legal)
S. 3013, 116th Cong. (2026), https://openamerica.io/bill/116-S-3013/.
Markdown link
[S. 3013: Encouraging Innovative Benefit Design to Lower Costs for Seniors Act](https://openamerica.io/bill/116-S-3013/)
Report a problem